Receipt of R&D Tax Incentive Refund
Released
Released
Announcement PDF
ASX Announcement – 16 March 2026
Resonance Health Ltd ABN: 96 006 762 492
141 Burswood Road, Burswood, WA 6100, AUSTRALIA Postal: PO Box 108, Victoria Park, WA 6979, AUSTRALIA
www.resonancehealth.com T + 61 8 9286 5300 info@resonancehealth.com
RECEIPT OF RESEARCH & DEVELOPMENT TAX INCENTIVE REFUND
Resonance Health Limited (Resonance or Company) (ASX: RHT) is pleased to announce that
it has received a refund from the Australian Taxation O?ice (ATO) of $732,851.
This amount is the net di?erence between the Company’s Research and Development (R&D)
tax incentive refund for R&D performed in the FY2025 year totalling $832,959 and the total
amount of income taxation payable by the Company given its FY2025 financial performance,
totalling $100,108.
This cash refund amount further adds to the Company’s cash at bank which will be reported in
the March 2026 Appendix 4C & Quarterly Activities Report.
Further Information:
https://investors.resonancehealth.com
This announcement has been authorised for release in accordance with the delegated
authority of the Board of Directors of Resonance Health Limited.
For further information:
Andrew Harrison
Managing Director
E: andrewh@resonancehealth.com
P: +61 8 9286 5300
Page 2
About Resonance Health
Resonance Health is an Australian healthcare technology and services company. The Company’s services are
used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic
companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide
for providing high quality quantitative assessments essential in managing diseases and drug development.
Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for
a range of Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and to proudly carry ISO
13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some
of which incorporate Artificial Intelligence (AI), include:
§ FerriScan®, a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through
non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions.
Internationally recognised as the gold standard in LIC assessment.
§ FerriSmart®, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in
participants, calibrated against the global gold standard, FerriScan®.
§ HepaFatScan®, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver
tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
§ HepaFatSmart ®, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of
liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
§ LiverSmart®, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and
HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
§ CardiacT2*, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers
a dual analysis of FerriScan® and CardiacT2*.
The Company has a development pipeline of additional medical imaging analysis products and services, including
the MRI Liver Fibrosis Project, aimed at accurately assessing the presence and progression of liver fibrosis
utilising non-invasive MRI analysis. The Company also has a clinical trials business which both manages clinical
trials in Australia and includes the site management operations of TrialsWest. Stakeholders, including clinicians,
participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to
follow Resonance Health on LinkedIn.
Disclaimer Forward Looking Statements
This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may
contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous
factors and uncertainties that could cause actual results to differ materially from those described. Forward looking
statements contained in this release may include statements about future financial and operating results, status of
regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could
affect Resonance Health’s products and services.
These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and
assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove
inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking
statement in which Resonance Health expresses an expectation or belief as to future results. There can be no
assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health
will not update forward-looking statements unless required by law.
Share your feedback
Discover